<DOC>
	<DOCNO>NCT00086333</DOCNO>
	<brief_summary>This open-label , randomized phase II trial monoclonal antibody ( mAb ) drug immunoconjugate , SGN-15 , administer weekly combination weekly docetaxel . The primary objective study determine optimal interval SGN-15 docetaxel use FDG-PET image surrogate marker response . In addition , clinical response rate , duration response , survival data collect .</brief_summary>
	<brief_title>FDG-PET Investigate SGN-15 Docetaxel Patients With Advanced Non-Small Cell Lung Carcinoma</brief_title>
	<detailed_description>SGN-15 mAb-drug immunoconjugate comprise chimeric anti-Lewis Y ( LeY ) mAb BR96 , conjugate doxorubicin . The LeY antigen find glycoprotein cell surface 90 % carcinoma lung . SGN-15 induces antitumor effect binding cell surface LeY antigen . It rapidly internalize release doxorubicin inside cell allow relative spar tissue normally affect non-specific chemotherapy . The study open patient good performance status ( ECOG 0 &lt; =2 ) stage IIIB IV NSCLC potentially curable surgery combine modality therapy receive prior lung cancer chemotherapy metastatic NSCLC . Patients register one two treatment sequence wil receive SGN-15 docetaxel 4 week cycle consist treatment weekly 3 week , follow week rest . Arm A receive combination o SGN-15 docetaxel day . Arm B receive combination SGN-15 follow docetaxel 3 day later . All patient undergo PET image prior treatment Day 22 . Patients achieve clinical response stable disease determine physical examination and/or traditional restaging study ( use establish RECIST criterion ) one 4 week cycle therapy eligible receive continue cycle SGN-15 docetaxel schedule clinical radiographic disease progression toxicity occur .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients pathologically confirm stage IIIB IV NSCLC minimum 1 measurable baseline target lesion receive prior chemotherapy metastatic disease eligible combine modality therapy curative intent Patients must ECOG performance status less equal 2 Patients must tumor block available documentation LeY antigen expression immunohistochemistry FDGPET imaging must complete PET center approve Seattle Genetics Patients must adequate bone marrow hepatic function Prior cytotoxic therapy metastatic NSCLC Those serious underlie nonmalignant disease Patients peripheral neuropathy &gt; Grade 2 exclude study Patients IDDM NIDDM Patients know active viral , bacterial , symptomatic fungal infection Concomitant antineoplastic experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Taxotere</keyword>
	<keyword>docetaxel</keyword>
	<keyword>taxanes</keyword>
</DOC>